- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Outpatient ASCT Safe, Results in Lower Rates of Febrile Neutropenia and Septicemia
Patients who undergo outpatient autologous stem cell transplantations (ASCTs) not only report lower costs and higher satisfaction, but they also have lower odds of developing febrile neutropenia and septicemia than patients who undergo inpatient ASCT, according to the results of a new analysis.
Autologous stem cell transplantation (ASCT) provides a therapeutic option for patients with multiple myeloma and lymphoma who are eligible for transplantation and achieved at least a partial response after combination chemotherapy. Although it can improve overall prognosis, it also has short-term complications, hospitalization, and high expenses. The first ASCT outpatient program was developed in 1993 in order to reduce costs and improve the quality of life for patients who require the transplantation.
Despite its benefits, outpatient ASCT has not been widely practiced because of concern over the risk of infection form a nonisolated practice site. However, patients who undergo outpatient ASCTs not only report lower costs and higher satisfaction, but they also have lower odds of developing febrile neutropenia and septicemia than patients who undergo inpatient ASCT, according to the results of a new analysis.
The meta-analysis included 9 studies, comprising of 1940 patients (740 in the outpatient-ASCT arm and 1200 in the inpatient-ASCT arm). Approximately 80% of the patients had multiple myeloma, 12.5% had lymphoma, and 0.9% had other hematologic malignancies. Two of the main end points observed were febrile neutropenia and septicemia.
After reviewing the data, investigators found that patients who underwent an outpatient ASCT had significantly lower odds of developing febrile neutropenia than patients who underwent an inpatient ASCT (odds ratio [OR] 0.44; 95% CI 0.29-0.65; P < .0001). The risk of septicemia was also significantly lower for outpatients than inpatients (OR 0.40, 95% CI 0.16-0.97, P = .04).
Complications, such as grade 2-3 mucositis and transplant-related mortality, were lower in the outpatient ASCT group as well, although these differences did not reach statistical significance (mucositis, P = .14; TRM, P = .12). Long term outcomes also favored outpatient ASCT, with the odds of surviving at 2-3 years being higher than for inpatient ASCT; however, this also did not reach statistical significance (P = .16).
This meta-analysis is the first to pool together a multitude of studies and conclude that patients who underwent outpatient ASCT had significantly lower odds at developing febrile neutropenia and septicemia than patients who underwent inpatient ASCT. Because of the cost savings and higher patient satisfaction rates, outpatient ASCT should utilized in more patients with multiple myeloma and lymphoma when the resources are available.
Reference:
Owattanapanich W, Suphadirekkul K, Kunacheewa C, Ungprasert P, Prayongratana K. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):1126. doi: 10.1186/s12885-018-5054-6.
The Long-term Social Value of Granulocyte Colony-Stimulating Factors
October 4th 2019Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Read More
Patients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.
Read More
Neutropenia Etiology Influences Resulting Hematologic Consequences
March 2nd 2019Hematological consequences of severe chronic neutropenia vary based on the underlying etiology of the condition, according to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition.
Read More
Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results
February 22nd 2019Initial results of a study have found that white blood cell counts and absolute neutrophil counts, which are well-established predictors of risk of infections or febrile neutropenia, can be accurately measured with a finger stick drop of blood and point-of-care hematology results.
Read More
